Ovarian Hyperstimulation Syndrome, Polycystic Ovarian Syndrome
Conditions
Brief summary
Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).
Detailed description
Dopamine agonists have been proposed as a prophylactic treatment for OHSS in women with high risk of OHSS, however the possible mechanism of action has not been clearly known. In experimental studies, inhibition of vascular endothelial growth factor based pathway was proposed as a possible action of mechanism of dopamine agonists. However the role hepatocyte growth factor (HGF), insulin like growth factor-I (IGF-I), inhibin B and antimullerian hormone (AMH) on cabergoline action in OHSS prevention has not been known.
Interventions
DRUGCabergoline
Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
Sponsors
Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
23 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Development of more than 14 leading follicles larger than 10 mm and serum estradiol more than 3000 pg/ml at the end of ovulation induction with long luteal ovulation induction protocol. * Having the criteria of PCOS
Exclusion criteria
* Not having the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of follicular fluid AMH | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Concentrations of follicular fluid inhibin B | 1 year |
| Concentrations of follicular fluid HGF | 1 year |
Outcome results
None listed